PLK1 inhibitor

Boehringer Ingelheim

Treatment of cancer cells with Plk1 inhibitors is associated with disruption of the mitotic spindle, spindle checkpoint activation and prolonged mitotic arrest in prometaphase (“polo-arrest”), which subsequently leads to cell death by apoptosis.

Polo-like kinases (Plk) are cell-cycle proteins that are important regulators of a cell’s passage through cell division
Plk1 is the best characterised of the 4 known human Plks. Its function is to control the progress of cells through mitosis and cell-cycle regulation
In many human cancers, high expression of Plk1 is thought to be associated with invasive growth and a poor prognosis
Treatment with a Plk1 inhibitor may result in tumour growth inhibition and regression in multiple animal models of human cancer
Boehringer Ingelheim is evaluating the therapeutic potential of agents targeting the cell cycle

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on